Bofanglutide, a novel GLP-1 RA, demonstrated significant weight loss and metabolic improvements with acceptable safety in Chinese adults with obesity in a clinical trial.
China's own GLP-1Domestically developed bofanglutide brings GLP-1 therapy access to China's 50+ million obese adults
What the researchers found
Bofanglutide (novel GLP-1 RA): significant weight loss and metabolic improvements with acceptable safety in Chinese adults with obesity.
Why it matters
China has one of the largest obese populations globally. A domestically developed GLP-1 drug provides accessible treatment.
How the study worked
Clinical trial evaluating bofanglutide efficacy and safety in Chinese adults with obesity.
What this study cannot tell us
Clinical trial details in full paper. Chinese population only.
How to read the evidence
Clinical trial in Chinese population.
When this study was published
Published in 2025.
The bigger picture
Domestic GLP-1 drug development in China could dramatically improve access to effective obesity treatment for the world's most populous nation.
Questions still open
- How does bofanglutide compare to semaglutide and tirzepatide?
- Will bofanglutide be significantly cheaper than imported GLP-1 drugs?
- What is bofanglutide's specific pharmacological profile?
Common questions
What is bofanglutide?
Is it available outside China?
Read the original research
Efficacy and safety of bofanglutide, a GLP-1 receptor agonist, in Chinese adults with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial.
Signal transduction and targeted therapy, 11(1)
Citation
Ji, Linong; Gao, Leili; Tian, Junhang; Dong, Ruihua; Zhang, Zhongtao; Shu, Hongyan; Zhao, Jing; Zhao, Liyuan; He, Anshun; Xie, Tian; Li, Yue; Chen, Wei. (2026). Efficacy and safety of bofanglutide, a GLP-1 receptor agonist, in Chinese adults with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial.. Signal transduction and targeted therapy, 11(1). https://doi.org/10.1038/s41392-026-02586-8